BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 20944490)

  • 1. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
    Komori S; Osada S; Mori R; Matsui S; Sanada Y; Tomita H; Tokuyama Y; Takahashi T; Yamaguchi K; Yoshida K
    Pancreas; 2010 Nov; 39(8):1284-92. PubMed ID: 20944490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
    Oguri T; Achiwa H; Bessho Y; Muramatsu H; Maeda H; Niimi T; Sato S; Ueda R
    Lung Cancer; 2005 Sep; 49(3):345-51. PubMed ID: 15993511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer.
    Yabushita Y; Mori R; Taniguchi K; Matsuyama R; Kumamoto T; Sakamaki K; Kubota K; Endo I
    Anticancer Res; 2017 May; 37(5):2465-2476. PubMed ID: 28476815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
    Tsujie M; Nakamori S; Nakahira S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Anticancer Res; 2007; 27(4B):2241-9. PubMed ID: 17695509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil.
    Kurata N; Fujita H; Ohuchida K; Mizumoto K; Mahawithitwong P; Sakai H; Onimaru M; Manabe T; Ohtsuka T; Tanaka M
    Int J Oncol; 2011 Aug; 39(2):473-82. PubMed ID: 21617862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy.
    Murata Y; Hamada T; Kishiwada M; Ohsawa I; Mizuno S; Usui M; Sakurai H; Tabata M; Ii N; Inoue H; Shiraishi T; Isaji S
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):413-25. PubMed ID: 21898089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
    Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd).
    Nishio R; Tsuchiya H; Yasui T; Matsuura S; Kanki K; Kurimasa A; Hisatome I; Shiota G
    Cancer Sci; 2011 Mar; 102(3):622-9. PubMed ID: 21205085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma.
    Toriumi F; Kubota T; Saikawa Y; Yoshida M; Otani Y; Watanabe M; Kumai K; Kitajima M
    Anticancer Res; 2004; 24(4):2455-63. PubMed ID: 15330198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
    Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
    Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TS and DPD mRNA levels on formalin-fixed paraffin-embedded specimens as predictors for distant recurrence of rectal cancer treated with preoperative chemoradiotherapy.
    Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Inoue Y; Kobayashi M; Miki C; Kusunoki M
    J Surg Oncol; 2012 May; 105(6):529-34. PubMed ID: 22006578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
    Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
    Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sueda T
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S646-55. PubMed ID: 22086444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines.
    Ando T; Ishiguro H; Kuwabara Y; Kimura M; Mitsui A; Sugito N; Mori R; Ogawa R; Katada T; Fujii Y
    Dis Esophagus; 2008; 21(1):15-20. PubMed ID: 18197934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
    Amatori F; Di Paolo A; Del Tacca M; Fontanini G; Vannozzi F; Boldrini L; Bocci G; Lastella M; Danesi R
    Pharmacogenet Genomics; 2006 Nov; 16(11):809-16. PubMed ID: 17047489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
    Nita ME; Tominaga O; Nagawa H; Tsuruo T; Muto T
    Hepatogastroenterology; 1998; 45(24):2117-22. PubMed ID: 9951876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
    Réjiba S; Bigand C; Parmentier C; Hajri A
    Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma.
    Fujii R; Seshimo A; Kameoka S
    Int J Clin Oncol; 2003 Apr; 8(2):72-8. PubMed ID: 12720098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.